Data-Driven Realism: Why Every Oncologist Must Analyze and Publish Their Clinical Outcomes

Sandeep Muzumder

doi:10.1055/s-0045-1812850

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1812850

Perspective

Data-Driven Realism: Why Every Oncologist Must Analyze and Publish Their Clinical Outcomes

Authors

Sandeep Muzumder

¹Department of Radiation Oncology, Apollo Hospital, Bhubaneswar, Odisha, India

Abstract

Volltext

Referenzen

References
1 Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine 2024; 78 (78) 102915
2 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
3 Llovet JM, Ricci S, Mazzaferro V. et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
4 Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 2016; 21 (09) 1113-1120
5 Templeton AJ, Vera-Badillo FE, Wang L. et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24 (12) 2972-2977
6 Tannock IF, de Wit R, Berry WR. et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15) 1502-1512
7 Bonner JA, Harari PM, Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354 (06) 567-578
8 Albarmawi H, Cullen KJ, Mehra R, Onukwugha E, Goloubeva O. Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer. J Comp Eff Res 2022; 11 (08) 595-607
9 Stanbouly D, Philipone E, Morlandt AB, Kaleem A, Chuang SK, Patel N. Adverse events secondary to cetuximab therapy in head & neck cancer therapy and risk factors for serious outcomes. Oral Oncol 2022; 131: 105952
10 Krishnamurthy S, Ahmed I, Bhise R. et al. The dogma of cetuximab and radiotherapy in head and neck cancer - a dawn to dusk journey. Clin Transl Radiat Oncol 2022; 34: 75-81
11 Prakash G, Bakhshi S, Raina V. et al. Characteristics and pattern of mortality in cancer patients at a tertiary care oncology center: report of 259 cases. Asian Pac J Cancer Prev 2010; 11 (06) 1755-1759
12 Penninckx B, Van de Voorde WM, Casado A, Reed N, Moulin C, Karrasch M. A systemic review of toxic death in clinical oncology trials: an Achilles' heel in safety reporting revisited. Br J Cancer 2012; 107 (01) 1-6
13 Yang P, Zheng Y, Chen J. et al. Immediate risk of non-cancer deaths after a cancer diagnosis. BMC Cancer 2021; 21 (01) 963
14 Babu A, Noel Alexander F H, Muzumder S, Srikantia N, Udayashankar AH. Sepsis surveillance in patients with head-and-neck cancer undergoing chemo-radiation. Support Care Cancer 2024; 32 (11) 724
15 Khoja L, McGurk A, O'Hara C, Chow S, Hasan J. Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre. Eur J Cancer 2015; 51 (02) 233-240
16 Feliu J, Pinto A, Basterretxea L. et al. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer. J Clin Med 2021; 10 (08) 1615
17 https://www.fda.gov/media/120060/download